Loading grant details…
Colorectal Cancer (CRC) Prevention by Urolithin A in Rodent CRC models
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | Research Inst of Fox Chase Can Ctr |
| Country | United States |
| Start Date | Jul 10, 2023 |
| End Date | Jul 09, 2026 |
| Duration | 1,095 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10885222 |
Grant Description
Colorectal cancer (CRC) is the third most common cancer diagnosed in the United States as per the current estimates of The American Cancer Society.
The number of CRC cases in the United States for 2022 are 106,180 new cases of colon cancer and 44,850 new cases of rectal cancer. The lifetime risk of developing CRC is about 1 in 23 (4.3%) for men and 1 in 25 (4.0%) for women.
CRC is also the third leading cause of cancer-related deaths in men and in women, and the second most common cause of cancer deaths when numbers from both sexes are combined.
Although changes in lifestyle-related risk factors, improved CRC treatments, and early screening has helped reduce the diagnosis and overall death rates considerably over the years, there has been a steady increase in CRC incidence and death rate among younger adults (
All Grantees
Research Inst of Fox Chase Can Ctr
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
